Lam NP. Hepatitis C: natural history, diagnosis, and management. Am J Health Syst Pharm 1999; 56(10): 961–76 PubMedCAS Google Scholar
Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000; 30(2): 125–43 ArticlePubMedCAS Google Scholar
Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31 Suppl. 1: 54–60 ArticlePubMed Google Scholar
Webster G, Barnes E, Brown D, et al. HCV genotypes — role in pathogenesis of disease and response to therapy. Baillieres Best Pract Res Clin Gastroenterol 2000 Apr; 14(2): 229–40 ArticlePubMedCAS Google Scholar
Berenguer M, Wright TL. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies. Proc Assoc Am Physicians 1998 Mar-Apr; 110(2): 98–112 PubMedCAS Google Scholar
Alberti A. Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C. BioDrugs 1999; 12(5): 343–57 ArticlePubMedCAS Google Scholar
Zein NN, Abdulkarim AS, Brandhagen D, et al. Chronic hepatitis C infection (HCV) in the US: an insight into the natural history and evidence for a change in the epidemiology of HCV genotypes. Hepatology 1996 Oct; 24(4 Pt 2): 150A Google Scholar
Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000 Apr; 13(2): 223–35 ArticlePubMedCAS Google Scholar
Benvegnù L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48(1): 110–5 ArticlePubMed Google Scholar
Consensus Panel. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999 May; 30: 956–61 Article Google Scholar
Seeff LB, Miller RN, Rabkin CS, et al. 45 Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105–11 PubMedCAS Google Scholar
National Institutes of Health Consensus Development Conference Panel Statement. Managment of Hepatitis C. Hepatology 1997 Sep; 26(3) Suppl. 1: 2S–10S Article Google Scholar
Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20(1): 1–13 ArticlePubMedCAS Google Scholar
Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28(6): 1687–95 ArticlePubMedCAS Google Scholar
Touzet S, Kraemer L, Colin C, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. Eur J Gastroenterol Hepatol 2000; 12(6): 667–78 ArticlePubMedCAS Google Scholar
Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol 1999; 14 Suppl.: S12–8 ArticlePubMed Google Scholar
Gitnick G. Hepatitis C: controversies, strategies and challenges. Eur J Surg 1998; 164 Suppl. 582: 65–70 Google Scholar
Lindsay KL. Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons. J Hepatol 1999; 31 1: 232–6 Article Google Scholar
Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343(23): 1666–72 ArticlePubMedCAS Google Scholar
Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 Dec 7; 343: 1673–80 ArticlePubMedCAS Google Scholar
Trepo C, Lindsay K, Niederau C, et al. Pegylated interferon alfa-2b (PEG-intron) monotherapy is superior to interferon alfa-2b (INTRON-A) for the treatment of chronic hepatitis C. 35th Annual Meeting of the European Association for the Study of the Liver 2000 Apr 29–May 3; Rotterdam. J Hepatol 2000; 32 Suppl. 2
Sulkowski M, Reindollar R, Clin C, et al. Combination therapy with PEGinterferon α-2a (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): a phase II open-label study [abstract]. Hepatology 1999; 30: 197A Google Scholar
Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis 2000; 20(2): 185–99 ArticlePubMedCAS Google Scholar
Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 Aug; 34: 395–403 ArticlePubMedCAS Google Scholar
Blatt LM, Davis JM, Klein SB, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996 Jul; 16: 489–99 ArticlePubMedCAS Google Scholar
Klein SB, Blatt LM, Taylor MW. Cell surface binding characteristics correlate with consensus type I interferon enhanced activity. J Interferon Cytokine Res 1996; 16(1): 1–6 ArticlePubMedCAS Google Scholar
Tanaka S et al. Antitumor activity and immunomodulatory effect of interferon alfacon-1 (YM643). Clin Pharmacol Therapy 2000 Sep; 10(5): 19–27 Google Scholar
Alton K, Stabinsky Y, Richards R, et al. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs. In: De Maeyer E, Schellekens H, editors. The biology of the interferon system. Proceedings of the Second International TNO Meeting on the Biology of the Interferon System. Amsterdam: Elsevier Science Publishers, 1983: 119–28 Google Scholar
Fish EN, Banerjee K, Stebbing N. Efficacy of consensus interferon alpha against HSV-2 infections. Antiviral Res 1985; Suppl. 1: 191–7
Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon-Conl with natural recombinant interferons-α antiviral, anti-proliferative, and natural killer-inducing activities. J Interferon Res 1992 Feb; 12: 55–9 ArticlePubMedCAS Google Scholar
Koyama AH, Arakawa T, Adachi A. Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-α-2b. Microbes Infect 1999 Nov; 1: 1073–7 ArticlePubMedCAS Google Scholar
Reiter Z, Ozés ON, Blatt LM, et al. A possible role for interferon-α and activated natural killer cells in remission of AIDS-related Kaposi’s sarcoma: in vitro studies. J Acquir Immune Defic Syndr 1992; 5: 469–76 ArticlePubMedCAS Google Scholar
Klein SB, Blatt LM, Taylor MW. Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-α2a. J Interferon Res 1993 Oct; 13: 341–7 ArticlePubMedCAS Google Scholar
Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997 Sep; 26 (3 Suppl. 1): 112S–21S ArticlePubMedCAS Google Scholar
Azuma J. Phase I safety study of interferon alfacon-1 in health volunteers — pharmacodynamic response. Jpn Pharmacol Ther 1999; 27(3): 217–26 Google Scholar
Neidhart JA, Schmidt S, Rosenblum M, et al. Phase I study of recombinant methionyl human consensus interferon (rmetHuIF-Con1). J Biol Response Mod 1988; 7(3): 240–8 PubMedCAS Google Scholar
Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Virol 1981 Feb; 37(2): 755–8 PubMedCAS Google Scholar
Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997 Sep; 26: 747–54 CAS Google Scholar
Yao G-B, Fu X-X, Tian G-S, et al. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with α-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2000 Oct; 15: 1165–70 ArticlePubMedCAS Google Scholar
Lee WM, Reddy KR, Tong MJ, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1998 Nov; 28: 1411–5 CAS Google Scholar
Heathcote EJ, James S, Mullen KD, et al. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. Consensus Interferon Study Group. Hepatology 1999 Aug; 30: 562–6 CAS Google Scholar
Heathcote EJL, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon [published erratum appears in Hepatology 1998 Aug;28 (2):599]. Hepatology 1998 Apr; 27: 1136–43 ArticlePubMedCAS Google Scholar
Pockros PJ, Tong M, Lee WM, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. J Viral Hepat 1998 Jul; 5: 271–6 ArticleCAS Google Scholar
Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999 Sep; 30: 787–93 CAS Google Scholar
Everson GT, Jensen DM, Craig JR, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999; 30(1): 271–6 ArticlePubMedCAS Google Scholar
Jensen DM, Krawitt EL, Keeffe EB, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999 Dec; 94: 3583–8 CAS Google Scholar
Susuki H, Tango T, Consensus Interferon Research Group. A multicenter, randomised, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Submitted to Hepatology Research
Sjögren MH. High dose consensus interferon (CIFN): a treatment option for relapsers and non-responders to combined therapy with interferon and ribavirin. 35th Annual Meeting of the European Association for the Study of the Liver; 2000 Apr 30; Rotterdam
Sjögren MH. Interferon alfacon-1 in the treatment of hepatitis C. Satellite symposium at the Annual Meeting of the Italian Association for the Study of the Liver; 2001 Oct 20; Turin
Neumann AU, Layden TK, Reddy KR, et al. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response (SVR) following consensus interferon (Infergen) treatment. Hepatology 2000 Oct; 32 (4)
Kaiser S, Kreysel C, Hass H, et al. High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive patients with chronic hepatitis C. EASL Satellite Symposium, Apr 2000
Manns M, Zeuzem S, Rustgi V, et al. Daily interferon alfacon-1 (Infergen) therapy: interim results from an ongoing international clinical trial to compare daily interferon alfacon-1 therapy (9 mcg/48 weeks) to standard regimens of thrice weekly (tiw) interferon alfacon-1 (9 mcg) for treatment of chronic hepatitis C virus. 35th Annual Meeting of the European Association for the Study of the Liver; 2000 Apr 30; Rotterdam
Reddy RK, Layden T, Hollinger FB, et al. Interferon alfacon-1 induction therapy: a multicenter trial in subjects with chronic hepatitis C virus infection [abstract]. Hepatology 2000 Oct; 32(4): 369 Google Scholar
Sjögren MH, Holtzmuller K, Sjögren RW Interferon α-2b + ribavirin compared to CIFN + ribavirin in the treatment of chronic hepatitis C. 102nd Annual Meeting of the American Gastroenterological Association. Digestive Disease Week May 20–23. Available from: URL: http://www.ddw.org [Accessed 2001 Aug]
Bellobuono A. Combination therapy with consensus interferon and ribavirin: results of various trials. 35th Annual Meeting of the European Association for the Study of the Liver; 2000 Apr 30; Rotterdam
Neumann AU. Early HCV kinetics and baseline factors in response to consensus interferon. Satellite symposium at the 35th Annual Meeting of the European Association for the Study of the Liver; 2000 Apr 30; Rotterdam
Chow W-C, Boyer N, Pouteau M, et al. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998; 27(4): 1144–8 ArticlePubMedCAS Google Scholar
Thévenot T, Regimbeau C, Ratziu V, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepatitis 2001; 8: 48–62 Article Google Scholar
Perry CM, Wilde MI. Interferon-α-2a. A review of its use in chronic hepatitis C. BioDrugs 1998 Jul; 10(1): 65–89 CAS Google Scholar
Alberti A, Chemello L, Noventa F, et al. Therapy of hepatitis C: re-treatment with alfa interferon. Hepatology 1997; 26 Suppl. 1: 137S–42S ArticlePubMedCAS Google Scholar
Chemello L, Cavalletto L, Donada C, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997; 113: 1654–9 ArticlePubMedCAS Google Scholar
Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339(21): 1493–9 ArticlePubMedCAS Google Scholar
Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299–305 ArticlePubMedCAS Google Scholar
Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to inter-feron-β therapy. Hepatology 1997 Mar; 25(3): 750–3 ArticlePubMedCAS Google Scholar
Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–6 ArticlePubMedCAS Google Scholar
Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity— determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745–9 ArticlePubMedCAS Google Scholar
Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997 Sep; 26 (3 Suppl. 1): 122S–7S ArticlePubMedCAS Google Scholar
Craxi A, Magrin S, Fabiano C, et al. Host and viral features in chronic HCV infection: relevance to interferon responsiveness. Res Virol 1995; 146: 273–8 ArticlePubMedCAS Google Scholar
Yun ZB, Reichard O, Chen M, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C — importance for outcome of interferon treatment. Scand J Infect Dis 1994; 26: 263–70 ArticlePubMedCAS Google Scholar
Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351–4 PubMedCAS Google Scholar
Barnes E, Webster G, Whalley S, et al. Predictors of a favorable response to alpha interferon therapy for hepatitis C. Clin Liver Dis 1999; 3: 775–91 ArticlePubMedCAS Google Scholar
Hwang S-J, Lee S-D, Chan C-Y, et al. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. Am J Gastroenterol 1999 Sep; 94: 2496–500 ArticlePubMedCAS Google Scholar
Herion D, Hoofnagle JH. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 1997 Mar; 25(3): 769–71 ArticlePubMedCAS Google Scholar
Neumann AU, Reddy KR, Levi-Drummer R, et al. Dose-dependent effectiveness of consensus interferon alfacon-1 (Infergen) in blocking in-vivo HCV production [abstract]. Hepatology 2000 Oct; 32(4): 372 Google Scholar
Keeffe EB, Dusheiko GM, Tong MJ, et al. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther 1999 Dec; 5: 211–6 PubMedCAS Google Scholar
Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993; 18: 1319–25 ArticlePubMedCAS Google Scholar
lino S, Hino K, Kuroki T, et al. Treatment of chronic hepatitis C with high-dose interferon α-2b; a multicenter study. Dig Dis Sci 1993; 38: 612–8 Article Google Scholar
Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182: 1595–601 ArticlePubMedCAS Google Scholar
Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997 Sep; 26(3) Suppl. 1: 128S–32S ArticlePubMedCAS Google Scholar
Poynard T, McHutchison J, Goodman Z, et al. Is an ‘à la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31(1): 211–8 ArticlePubMedCAS Google Scholar
Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32(3): 647–53 ArticlePubMedCAS Google Scholar
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998 Oct 16; 47(RR-19): 1–39 Google Scholar
Brown Jr RS, Ascher NL, Lake JR, et al. The impact of surgical complications after liver transplantation on resource utilization. Arch Surg 1997; 132(10): 1098–103 ArticlePubMed Google Scholar
Koff RS, Fendrick M. Pharmacoeconomics of hepatitis C. P and T 2000; 25(9): 468–75 Google Scholar
McHutchison J, Woolley JM, Pianko S, et al. Cost effectiveness of interferon alfacon-1 (Infergen) therapy for patients with chronic hepatitis C and cirrhosis [abstract]. Hepatology 1999 Oct; 30(4): 482 Google Scholar
McHutchison JG, Woolley JM, Nyberg LM. Cost effectiveness of retreatment with consensus interferon for chronic hepatitis C [abstract]. Hepatology 1997 Oct; 26(4): 421 Google Scholar
Saab S, Han SH, Martin P. Relative cost-effectiveness for the retreatment of chronic hepatitis C [abstract 6716]. Gastroenterology 2000 Apr; 118 (4 Suppl. 2): A1483 Article Google Scholar
Zeuzem S. Treatment of chronic hepatitis C virus infection in patients with cirrhosis. J Viral Hepatitis 2000; 7(5): 327–34 ArticleCAS Google Scholar
Brass CA. Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection. Clin Ther 1998 May–Jun; 20: 388–97 ArticlePubMedCAS Google Scholar
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998 Nov 19; 339(21): 1485–92 ArticlePubMedCAS Google Scholar
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 Oct; 352: 1426–32 ArticlePubMedCAS Google Scholar
Sjögren MH, Wu G, Herrine SK, et al. High-dose interferon alfacon-1 is a treatment option for non-responders and relapsers to combined therapy with interferon and ribavirin [abstract]. Hepatology 2000 Oct; 32(4): 352A Google Scholar
Shiffman ML. PEGylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001; 3: 30–7 ArticlePubMedCAS Google Scholar
Schering-Plough Corporation, press release [online]. Available from: URL: http://www.schering-plough.com [Accessed 2001 Aug 8]